Breeding’s Hidden Constraint: Why Execution, Not Data, Will Define AgTech Winners
Editor’s note: “Cultivating Tomorrow” is a special series that shares insights from C-suite executives at leading AgTech companies, presented by AgTech PR. Its aim is to highlight the experiences of AgTech leaders driving agricultural transformation today. In this installment, Meiogenix CEO Ricardo Garcia de Alba argues execution — not prediction — will unlock stalled traits and define AgTech winners in 2026.
Heading into March in agtech is always a balancing act. Trade shows and investor meetings, on‑stage presentations on one side; pre‑season field activities and breeding decisions on the other. For agtech companies, this is the moment when we put our tools and models on display and show how we can unlock bottlenecks across the value chain.
For the last decade, as an industry, we’ve poured energy into improving prediction: AI, genomic selection, dense marker sets, better phenotyping. Those tools matter. I’ve seen them change how we design pipelines and make decisions. But when you step inside breeding programs, a different story plays out: the limiting factor is no longer knowing where the trait is, it’s being able to reach it on commercial timelines and terms.
When we talk with our customers, we often hear that they “know where the trait is” but still cannot get it into elite products at the speed, scale or quality they need. There are traits everyone believes in —especially in wild and exotic germplasm — that simply don’t make it into the market, not because product developers don’t care, but because biology refuses to cooperate with the timelines and economics of commercial plant breeding.
The fact is, there are wild types traits that it doesn’t matter if you do a million crosses, you will not be able to get the trait in your elite product. We estimate that roughly 25% of the high value genes in major crops are effectively unavailable today because those genes sit in regions that don’t recombine, or they’re tied up in linkage drag. There are traits everybody knows are valuable — disease resistance in a wild tomato line, stress tolerance in a corn, quality attributes in exotic germplasm — that never make it into commercial products. Not because people don’t care, but because the time, cost and risk of trying to separate the good from the bad just don’t pencil out.
In practical terms, that means we have accepted that a substantial portion of innovation in major crops is effectively off limits. We don’t always call it that, but we behave as if it were true. That’s the execution gap I worry about.
An Optimistic Argument for Radical Pragmatism
Before I joined Meiogenix in 2024, I spent 15 years at Corteva working across seed and crop protection. I had a front row seat to how hard it is to translate promise into impact at scale. That perspective is exactly what made Meiogenix so compelling to me.
When Meiogenix was founded in 2010 in Paris, the starting point wasn’t a crop — it was meiosis. Researchers at Institut Curie identified key meiotic proteins and found a way to use them to stimulate recombination, first in yeast and other model systems, while exploring where such a powerful lever could matter most. Plant breeding was always on the list, but only after conversations with potential partners and a hard look at where recombination was truly limiting progress did it become clear that the biggest unmet need was in crops.
That realization is what drew me in and why I left Corteva after a successful career to help lead a company focused on unlocking how plant breeding is done — and ultimately transform agriculture. I’m a consummate optimist, sometimes my excitement overflows when an opportunity is clear. But in agriculture, whether in the lab, office or field, optimism must be paired with pragmatism. Even with technology I feel this strongly about, the starting point could not be the platform itself. It must be the reality customers are living with today.
That’s why we spend so much time listening: where pipelines are slowing down; which traits have been parked because they’re “too hard”; how regulatory and consumer expectations are shaping what’s considered acceptable. Those conversations are often confidential and very specific, but patterns of opportunity are often clear.
Five Ways to Deliver Real Value in 2026
Capital hasn’t disappeared from agtech, but it has become more selective, favoring deployment‑ready tools and shorter time‑to‑acre, while long‑cycle bets on entirely new traits and crop protection face a tougher bar and a thinner funnel of investors willing to carry that risk. If you are building or leading an agtech company, you can’t afford to ignore where your customers are truly stuck or assume the market will keep underwriting long timelines without clear execution gains.
As we’ve evaluated our own value proposition, a few lessons have stood out for me:
- Start with the bottleneck, not the buzzword. Before you sell a platform, get painfully specific about where the pain is.
- Treat regulatory and market fit as part of the product, not an afterthought. A brilliant technology that creates regulatory headaches or consumer acceptance risk is a harder sell. Build with clear paths to approval and labeling baked into the value proposition.
- Earn proprietary insight, don’t rent generic “voice of customer.” Deep, confidential work with a few anchor breeding partners informed us more about real constraints than any conference panel. Protect that insight like IP and let it steer your roadmap.
- Measure yourself on acres and outcomes, not models and demos. In a more selective funding environment, you will be judged on traits advanced, timelines shortened and value unlocked — not on the elegance of your prediction layer alone.
- Focus on expanding what’s possible, not just what’s visible. Tools that unlock previously unreachable outcomes will define the next generation of category leaders.
As I often tell breeders, it’s not just about speed; it’s about a level of precision that wasn’t possible, even through millions of iterations. We can substantially accelerate the breeding process, but more importantly, we can open up additional value that has been out of reach. That is the heart of the execution question.
In my view, that is the standard we should hold ourselves to as agtech leaders: don’t just help customers see problems more clearly — help them do something they once thought was impossible.
Subscribe Today For
